Skip to content
EmergingResearch compoundReference only

Fladrafinil

Experimental wakefulness-promoting compound, a fluorinated version of adrafinil; not studied in humans, may strain the liver.

NootropicEugeroicEugeroicStimulantWakefulnessDopamineAnti-fatigue

Pharmacology

ClassEugeroic · Stimulant · Wakefulness
Primary targetDopamine transporter (DAT)
Targets3 receptor targets
EvidenceReference only
Affected systemsDopamineAnti-fatigue

Contents

Related comparisons

Adrafinil vs Fladrafinil

DETAILED OVERVIEW

What is Fladrafinil?

Fladrafinil is an experimental wakefulness-promoting compound, a version of adrafinil modified with fluorine and originally developed in France. There are no clinical trials in humans, it is not approved anywhere, it is banned in the United Kingdom, and elsewhere it is sold as a research chemical.

In the liver it is converted, like adrafinil, into an active substance resembling modafinil (another wakefulness-promoting drug), which acts on the brain's dopamine and alertness-regulating systems. The fluorine slows its breakdown in the liver, so it acts for longer, but the risk of liver damage rises: liver enzymes may increase with prolonged use. A reduction in aggression has also been described in animal studies. Side effects can include insomnia, anxiety, and higher blood pressure and pulse. It should be avoided in liver disease, cardiovascular disease, pregnancy and breastfeeding, and it may reduce the effect of hormonal contraceptives.

Mechanism

Modafinil-prodrug profile

Half-life

No validated human data

Legal status

Not approved anywhere

Receptor profile

  • Dopamine transporter (DAT)Moderate
  • Orexin (hypothalamic wake system)Moderate
  • Histamine (tuberomammillary system)Moderate

Safety

Side effects, stop signs, contraindications

Side effects · 7

  • Insomnia and disrupted sleep, especially with late dosing due to the 12-16 hour duration
  • Headache, a typical side effect of modafinil-class eugeroics
  • Anxiety, irritability and overstimulation, more pronounced at higher doses
  • Reduced appetite and dry mouth
  • Palpitations, raised blood pressure and heart rate from the dopaminergic-stimulant effect
  • Elevated liver enzymes and risk of hepatotoxicity with chronic use (as seen with adrafinil)
  • Tolerance development with repeated use

Contraindications · 6

  • No human clinical safety data, long-term effects unknown, not approved anywhere
  • Existing liver impairment, avoid with other hepatotoxic agents or alcohol (liver function monitoring warranted)
  • Cardiovascular disease, hypertension or arrhythmia due to the blood-pressure and heart-rate raising effect
  • Pregnancy and breastfeeding, safety not established
  • Anxiety disorders, avoid combining with other stimulants due to overstimulation
  • Its modafinil-like metabolite may reduce the efficacy of hormonal contraceptives (CYP3A4 induction)

Related Nootropics

Same therapeutic category

FAQ

FAQ

Fladrafinil is a modified, fluorinated version of the well-known wakefulness-promoting compound adrafinil, designed to be stronger and longer-lasting than the original. Per the description it produces a similar wakefulness-boosting effect to adrafinil, just more potent and longer-acting, and is also credited with an aggression-reducing profile. This is an experimental, poorly researched compound rather than an established, widely used substance.

Telegram

Have a question about Fladrafinil?

Reach out to us on Telegram for a personalized stack. We'll be happy to help.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

Structure & chemistry

TypeNootropic
FormulaC15H13F2NO3S
UpdatedOctober 13, 2026
MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 13, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.